Market Overview

Ascendiant Capital Maintains Strong Buy on Repros Therapeutics Inc., Lowers PT to $19.00

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Latest Ratings for RPRX

DateFirmActionFromTo
Sep 2014Piper JaffrayDowngradesOverweightNeutral
Nov 2013Piper JaffrayInitiates Coverage onOverweight
Nov 2013Laidlaw & Co.Initiates Coverage onBuy

View More Analyst Ratings for RPRX
View the Latest Analyst Ratings

Posted-In: News Price Target Analyst Ratings

 

Related Articles (RPRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters